HLB Group affiliates welcome Japan 바카라 전략 for talks on novel drug development, health supplements, and convergence technology collaboration
[by Yu, Suin] HLB Group announced on June 24 that key executives, including Chairman Azuma Akihiro of ACA (Asia Capital Alliance), a leading Japanese private equity fund management firm, visited South Korea to tour the group’s major affiliates and engage in discussions regarding strategic collaboration in the healthcare sector.
ACA is an investment firm specializing in healthcare-focused investment across Asia, with around USD 1.4 billion (approximately KRW 1.9 trillion) in assets under management. Its representative subsidiary, ‘ACA NEXT,’ is a senior comprehensive service provider established in 2016. In a recent development, HLB Global and HLB Genex jointly acquired a 14.4% stake in ACA NEXT last month, making them the second-largest shareholder following ACA.
The visit to Korea was organized to deepen ACA’s understanding of HLB Group’s overall business operations and to explore the potential for concrete collaboration in the Japanese market. On the first day of the visit, the ACA delegation toured key affiliates, including HLB Healthcare Division, HLB Genex, and HLB Panagene, to directly assess the group’s manufacturing capabilities and technological foundation. During the visit, both parties engaged in in-depth discussions on the globalization potential of each company’s core technologies and products, with a particular focus on cooperative models for distribution and joint research and development (R&D) in Japan.
On the second day, the ACA delegation visited HLB NeuroTobe and the Korea Advanced Institute of Science and Technology (KAIST) to gain a closer understanding of HLB’s next-generation new drug development businesses and its R&D pipeline. The discussion also explores concrete, demand-driven collaboration models, such as clinical trials and co-development in Japan, particularly centered on therapeutic areas including brain diseases and oncology.
The ACA delegation took particular interest in HLB’s advanced research capabilities and extensive experience in conducting global clinical trials. Building on this, both parties expressed a positive outlook on the potential for joint entry into the senior healthcare and medical services market. HLB Group intends to leverage ACA’s visit as an opportunity to establish a practical cooperation model between Korea and Japan across the entire healthcare spectrum, including health functional foods and new drug development. The group also aims to accelerate the export of its technologies to the Japanese market and broader Asian region by capitalizing on ACA’s investment resources and expansive network.
“This visit by the ACA delegation has created an important opportunity to connect the group’s advanced healthcare technologies and global business capabilities with the Japanese market,” an HLB Group official said. “We will continue to actively explore joint business opportunities across Asia through strategic collaboration with ACA.”